Compare

Raisio plc/€RAIVV

1D1W1M3M6MYTD1Y5YMAX

About Raisio plc

Raisio plc is a Finnish company specializing in the production and sale of healthy, responsibly produced food and ingredients. Its core products include grain-based foods, plant-based proteins, and functional food ingredients marketed under brands such as Benecol® and Elovena®. Founded in 1939, Raisio is headquartered in Raisio, Finland, and operates production facilities in Finland with key offices in the UK, Ireland, Poland, and Ukraine. The company exports to over 40 markets worldwide and employs approximately 350 people. Raisio's strategic focus on health and sustainability is evident in its commitment to producing heart-healthy products and achieving a high percentage of carbon-neutral energy usage.
Ticker
€RAIVV
Sector
Consumer Essentials
Primary listing
XHEL
Employees
367
Headquarters
Raisio, Finland
Website
www.raisio.com

Raisio plc Metrics

BasicAdvanced
€352M
18.87
€0.12
-
€0.15
6.75%

What the Analysts think about Raisio plc

Analyst ratings (Buy, Hold, Sell) for Raisio plc stock.
Analyst projections of the future price of Raisio plc stock.

Bulls say / Bears say

Breakfast, Snacking & Food Solutions grew strongly in the first half, with Elovena performing well in Finland and export demand supporting Food Solutions. That gives Raisio a clear growth engine outside its weaker Heart Health business. (Raisio)
Raisio has completed the Nokia oat mill capacity expansion and says the site is now fully operational. Its pilot plant and planned research facilities could support new oat and fibre products over time. (Raisio)
Inderes estimated Raisio had €58 million of net cash and highlighted a roughly 6% dividend yield alongside modest earnings-based valuation. Those features may support returns if the company manages its cash well. (Inderes)
Raisio cut its 2026 outlook: it now expects sales to stay flat and comparable operating profit to be flat or slightly lower, citing weaker late-year sales and higher ERP costs. This reverses its earlier forecast for growth in both. (Raisio)
Heart Health sales were slightly lower in the first half, and the company cited weaker consumer volumes, currency effects and Benecol rebranding costs as pressures on profitability. This leaves a key business unit struggling to contribute growth. (Raisio)
Inderes says sales growth was only about 1% a year from 2025 to the first half of 2026, below the pace needed for Raisio’s growth ambitions. CEO and CFO departures have added uncertainty over whether the strategy can deliver. (Inderes)
Data summarised monthly by Lightyear AI. Last updated on 6 Nov 2026.

Raisio plc Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

Raisio plc Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.